7 October
2024
Assura plc
Trading update for the first
half ended 30 September 2024
Assura plc ("Assura"), the
diversified healthcare REIT, today announces its Trading Update for
the six months to 30 September 2024.
Jonathan Murphy, CEO, said:
"We have made strong strategic
progress in the first half of the year. The £500 million
acquisition in August of a private hospital portfolio accelerates
the delivery of our broader healthcare strategy while our £250
million joint venture with USS diversifies our funding. We are also
very pleased to have been certified as the first FTSE 250 B Corp
recognising our high standards of social and environmental
performance.
"The purchase of 14 UK private
hospitals materially increases our exposure to the structurally
supported private healthcare market as we continue to diversify our
offering to meet changing UK healthcare demands. The joint venture
with USS, the UK's leading private pension scheme, provides a new
source of funding and opportunities to recycle capital into our
growth pipeline.
"The need for investment in
healthcare infrastructure was starkly outlined by the recent Lord
Darzi report - which found the primary care estate to be plainly
not fit for purpose and more than 1 million people to be waiting
for community services. We are at an inflexion point in the UK,
with structural changes to the delivery of healthcare services, the
Government targeting preventative services in a community setting,
and rising demand for private providers. Assura has firmly
positioned itself to facilitate this change, being well-placed to
work with all healthcare providers to deliver high-quality,
sustainable facilities for the long-term.."
Delivery against our strategic objectives
•
Portfolio of 14 private hospitals acquired for £500 million: day 1
rental income of £29.4 million, WAULT of 26 years, 100% subject to
annual index-linked rent reviews, let to tier 1 private healthcare
providers with strong rent cover of 2.3 times
•
Portfolio now stands at 625 properties with an annualised rent roll
of £179.1 million (March 2024: £150.6 million)
•
Three developments completed with a total combined spend of £46
million; GP surgery in Shirley, ambulance hub at Bury St Edmunds
and our largest in-house development project to date of the
Northumbria Health & Care Academy at Cramlington
•
Positive progress on rent reviews, 129 settled in the first half,
covering £20.4 million of existing rent and generating an uplift of
£1.7 million (8.2% uplift on previous passing rent, 3.0% on an
annualised basis)
•
Initial tranche of seven assets agreed for transfer to joint
venture with USS
•
Completed seven asset enhancement capital projects (total spend
£3.0 million) and seven lease regears (existing rent £0.6 million);
on site with a further four capital projects (total spend £5.6
million)
•
Quarterly dividend increased by 2.4% to 0.84 pence per share, as
announced at the full year results, with effect from the July 2024
payment
Pipeline of opportunities for strategic expansion and further
growth
•
Advanced discussions taking place for the disposal of 12
assets
•
Currently on site with five developments; total cost of £44 million
with £27 million remaining to be spent. On site schemes include two
net zero carbon buildings in the UK (one GP medical centre, one NHS
children's therapy centre) and three developments for the HSE in
Ireland.
•
Pipeline of 14 capital asset enhancement projects (projected spend
£8.8 million) over the next two years
• 32
lease re-gears covering £3.9 million of existing rent roll in the
current pipeline
Strong and sustainable financial position
•
Weighted average interest rate 3.0% (March 2024: 2.3%); all drawn
debt on fixed rate basis
•
Weighted average debt maturity of 5.1 years, limited refinancing on
drawn debt over the next 3 years. Over 40% of drawn debt matures
beyond 2030, with our longest maturity debt at our lowest
rates
• A-
rating reaffirmed by Fitch in August following private hospital
portfolio acquisition
• Net
debt of £1,575 million (March 2024: £1,217 million) on a fully
unsecured basis with cash and undrawn facilities of £143
million
Full results for the six months
ended 30 September 2024 will be announced on 14 November
2024.
- Ends
-
For more information, please
contact:
Assura plc Jayne Cottam, CFO
David Purcell, Investor Relations
Director
|
Tel: 0161 515
2043 Email: Investor@assura.co.uk
|
FGS Global
Gordon Simpson
Grace Whelan
|
Tel: 0207 251 3801
Email: Assura@fgsglobal.com
|
Notes to Editors
Assura plc is the UK's leading
diversified healthcare REIT. Assura enables better health outcomes
through its portfolio of more than 600 healthcare buildings, from
which over six million patients are served.
A UK REIT based in Altrincham,
Assura is a constituent of the FTSE 250 and the EPRA* indices. As
at 31 March 2024, Assura's portfolio was valued at £2.7 billion and
has a strong track record of growing financial returns and
dividends for shareholders.
At Assura, we BUILD for health,
having developed over 100 new healthcare buildings in our history,
and at the heart of our strategy sits The Bigger Picture; Healthy
Environment (E), Healthy Communities (S), Healthy Business
(G).
Further information is available
at www.assuraplc.com
*EPRA is a
registered trademark of the European Public Real Estate
Association